NeurOp is a biotechnology company developing medicines for the treatment of central nervous system (CNS) disorders including stroke, severe pain, subarachnoid hemorrhage (SAH), and treatment-resistant depression. Its proprietary compounds selectively inhibit the glutamate ionotropic receptor (GluN2B) subunit of neuronal n-methyl-d-aspartate (NMDA) receptors and are designed for potential therapeutic benefit.